Compare Repligen Corporation Common Stock (RGEN) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Repligen Corporation Common Stock trades at $181.78 (market cap $11.31B), while iShares Broad USD Investment Grade Corporate Bond trades at $49.2 (market cap $17.73B). The key difference: iShares Broad USD Investment Grade Corporate Bond is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and iShares Broad USD Investment Grade Corporate Bond for 46 Days on average.
| RGEN | USIG | |
|---|---|---|
Market Cap | $11.31B | $17.73B |
Volume | 1,216,919 | 2,036,622 |
Sector | Health | Fixed Income |
52-Week High | $194.57 | $52.69 |
52-Week Low | $102.87 | $48.54 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $11.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
USIG trades at $48.84 with minimal daily movement (+0.03%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators remain neutral. The stock faces resistance at $49 across multiple levels. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake by 0.9% in Q2 2026.
The outlook remains cautious due to bearish technical signals and limited fundamental data availability. Investment opportunities exist through consistent dividend payments, with three distributions scheduled for H2 2026. Key risks include market volatility and the need for clearer financial disclosures to assess valuation metrics properly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
